The Mesoblast Limited (ASX: MSB) share price jumped out of the blocks in early trade on Friday. Today’s early moves comes after the Aussie biotech’s latest quarterly report to the market.
At the time of writing, the Mesoblast share price is trading up 3.23% at $2.40.
Why is the Mesoblast share price climbing higher?
Mesoblast provided an update on its pipeline of late-stage product candidates and an activity report for the second quarter ended 31 December 2020 (Q2 2020). That included Phase 3 trials of rexlemestrocel-L for advanced chronic heart failure.
Mesoblast CEO, Dr Silviu Itescu, was “very pleased” to see significant reductions in cardiac mortality and major vascular events.
The “strong data” from this randomised controlled Phase 3 trial underpin Mesoblast’s discussions with potential strategic partners. The results will also support the company’s interactions with United States Food and Drug Administration (FDA), Dr Itescu said.
Quarterly highlights
The Mesoblast share price has climbed higher in early trade following the update on a number of key developments.
Key highlights within the quarterly report include:
- Revenues from royalties on TEMCELL HS Inj. sales for the second quarter climbed to US$2.1 million compared to US$2.0 million in Q2 2019.
- Mesoblast amended its existing agreement with Hercules to extend the interest-only loan period up to March 2022, subject to achieving certain milestones.
- The Aussie biotech is waiting on 60-day results from its COVID-19 ARDS trial in Q1 2021. The results will be analysed by Mesoblast and Novartis to identify meaningful clinical outcomes.
- Mesoblast’s cash on hand at period-end of US$77.5 million. The company may receive up to an additional US$92.5 million through existing financing facilities and strategic partnerships.
- Mesoblast intends to meet with the FDA during Q1 2021 for further discussion. The company is seeking accelerated approval of remestemcel-L in the treatment of children with steroid-refractory acute graft-versus-host disease (SR-aGVHD).
The Mesoblast share price has been on somewhat of a rollercoaster ride in recent months. Shares in the Aussie biotech are down 20.3% in the last 12 months but have climbed 6.2% in January 2021
Our TOP healthcare stock is trading at a 30% discount to its highs
If there’s one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he’s staked $209k of our own company money on it. Forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
Find out the name of this stock
As of 2.11.2020
More reading
- Here are the 10 most shorted shares on the ASX
- Afterpay and BrainChip were some of the most traded ASX shares last week
- Here are the 10 most shorted shares on the ASX
- ASX 200 Weekly Wrap: ASX drops despite promises of more US stimulus
- These were the best performing ASX 200 shares last week
Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Why the Mesoblast (ASX:MSB) share price is rising today appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/36lxeTC
Leave a Reply